HDAC6 and melanoma: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1).